Tezosentan in patients with acute heart failure: design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS) - PubMed (original) (raw)
doi: 10.1016/j.ahj.2005.04.035.
John J V McMurray, Robert C Bourge, John G F Cleland, Gadi Cotter, Guillaume Jondeau, Henry Krum, Marco Metra, Christopher M O'Connor, John D Parker, Guillermo Torre-Amione, Dirk J Van Veldhuisen, Aline Frey, Maurizio Rainisio, Isaac Kobrin; VERITAS Investigators
Affiliations
- PMID: 16084150
- DOI: 10.1016/j.ahj.2005.04.035
Tezosentan in patients with acute heart failure: design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS)
John R Teerlink et al. Am Heart J. 2005 Jul.
Abstract
Background: Endothelin 1 is a potent endogenous vasoconstrictor neurohormone, and endothelin 1 plasma concentrations predict adverse outcomes in patients with acute heart failure (AHF). Tezosentan, an intravenous endothelin receptor antagonist, improved hemodynamics in patients with AHF; however, its effects on morbidity and mortality have not been evaluated.
Methods: The VERITAS program consists of 2 identical, double-blind, randomized, placebo-controlled, concurrently conducted trials (VERITAS-1 and VERITAS-2), performed in 150 centers in Europe, Israel, Australia, and North America. The program is designed to enroll at least 1760 patients hospitalized with dyspnea at rest because of AHF requiring intravenous therapy. In addition to conventional therapy, patients are randomized to receive tezosentan (5 mg/h for 30 minutes, then 1 mg/h for 24-72 hours) or matching placebo. The 2 prespecified primary end points are the incidence of death or worsening heart failure at 7 days in the combined studies and the change from baseline in dyspnea over the first 24 hours of treatment, measured using a visual analog scale in VERITAS-1 and VERITAS-2, individually.
Results: Enrollment started in April 2003, and the program was discontinued in November 2005 because of the low probability of achieving a significant treatment effect.
Conclusions: No currently available agents have been shown in a prospective, randomized, clinical trial to improve outcomes in patients with AHF. Thus, the VERITAS program will provide valuable insights into the effect of tezosentan on clinical outcomes in patients with AHF, as well as hemodynamics and clinical symptoms.
Similar articles
- Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials.
McMurray JJ, Teerlink JR, Cotter G, Bourge RC, Cleland JG, Jondeau G, Krum H, Metra M, O'Connor CM, Parker JD, Torre-Amione G, van Veldhuisen DJ, Lewsey J, Frey A, Rainisio M, Kobrin I; VERITAS Investigators. McMurray JJ, et al. JAMA. 2007 Nov 7;298(17):2009-19. doi: 10.1001/jama.298.17.2009. JAMA. 2007. PMID: 17986694 Clinical Trial. - The dual endothelin receptor antagonist tezosentan acutely improves hemodynamic parameters in patients with advanced heart failure.
Schalcher C, Cotter G, Reisin L, Bertel O, Kobrin I, Guyene TT, Kiowski W. Schalcher C, et al. Am Heart J. 2001 Aug;142(2):340-9. doi: 10.1067/mhj.2001.116760. Am Heart J. 2001. PMID: 11479476 Clinical Trial. - Tezosentan in patients with acute heart failure and acute coronary syndromes: design of the fourth Randomized Intravenous Tezosentan Study (RITZ-4).
O'Connor CM, Gattis WA, Adams KF Jr, Shah MR, Frey A, Gheorghiade M; Randomized Intravenous Tezosentan Study Investigators. O'Connor CM, et al. Am Heart J. 2003 Feb;145(2 Suppl):S58-9. doi: 10.1067/mhj.2003.156. Am Heart J. 2003. PMID: 12594454 Clinical Trial. No abstract available. - Tezosentan in the treatment of acute heart failure.
Tovar JM, Gums JG. Tovar JM, et al. Ann Pharmacother. 2003 Dec;37(12):1877-83. doi: 10.1345/aph.1D080. Ann Pharmacother. 2003. PMID: 14632537 Review. - Tezosentan. Actelion/Genentech.
Rossetti E, De Servi S. Rossetti E, et al. Curr Opin Investig Drugs. 2003 Mar;4(3):323-8. Curr Opin Investig Drugs. 2003. PMID: 12735233 Review.
Cited by
- Optimizing Hypertensive Acute Heart Failure Management with Afterload Reduction.
Collins S, Martindale J. Collins S, et al. Curr Hypertens Rep. 2018 Feb 24;20(1):9. doi: 10.1007/s11906-018-0809-7. Curr Hypertens Rep. 2018. PMID: 29478124 Review. - Pharmacological interventions for heart failure in people with chronic kidney disease.
Lunney M, Ruospo M, Natale P, Quinn RR, Ronksley PE, Konstantinidis I, Palmer SC, Tonelli M, Strippoli GF, Ravani P. Lunney M, et al. Cochrane Database Syst Rev. 2020 Feb 27;2(2):CD012466. doi: 10.1002/14651858.CD012466.pub2. Cochrane Database Syst Rev. 2020. PMID: 32103487 Free PMC article. - High prevalence of occult pulmonary venous hypertension revealed by fluid challenge in pulmonary hypertension.
Robbins IM, Hemnes AR, Pugh ME, Brittain EL, Zhao DX, Piana RN, Fong PP, Newman JH. Robbins IM, et al. Circ Heart Fail. 2014 Jan;7(1):116-22. doi: 10.1161/CIRCHEARTFAILURE.113.000468. Epub 2013 Dec 2. Circ Heart Fail. 2014. PMID: 24297689 Free PMC article. - Contrasting actions of endothelin ET(A) and ET(B) receptors in cardiovascular disease.
Schneider MP, Boesen EI, Pollock DM. Schneider MP, et al. Annu Rev Pharmacol Toxicol. 2007;47:731-59. doi: 10.1146/annurev.pharmtox.47.120505.105134. Annu Rev Pharmacol Toxicol. 2007. PMID: 17002597 Free PMC article. Review. - The Impact of Worsening Heart Failure in the United States.
Cooper LB, DeVore AD, Michael Felker G. Cooper LB, et al. Heart Fail Clin. 2015 Oct;11(4):603-14. doi: 10.1016/j.hfc.2015.07.004. Epub 2015 Aug 11. Heart Fail Clin. 2015. PMID: 26462100 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous